Vertex Pharmaceuticals stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, with an increase from 70 to 74.
When looking for the best stocks to buy and watch, keep a close on eye on relative price strength.
This unique rating identifies market leadership by using a 1 (worst) to 99 (best) score that shows how a stock's price action over the trailing 52 weeks matched up against all other stocks.
Over 100 years of market history shows that the market's biggest winners tend to have an RS Rating north of 80 in the early stages of their moves. See if Vertex Pharmaceuticals can continue to show renewed price strength and hit that benchmark.
Looking For The Best Stocks To Buy And Watch? Start Here
Is Vertex Pharmaceuticals Stock A Buy?
Vertex Pharmaceuticals stock is trying to complete a flat base with a 324.85 entry. See if the stock can clear the breakout price in heavy trading.
The biotech firm showed 14% EPS growth last quarter, while sales growth came in at 18%. The company is expected to report its latest results on or around Feb. 1.
Vertex Pharmaceuticals stock holds the No. 3 rank among its peers in the Medical-Biomed/Biotech industry group. Genmab ADR and BioMarin Pharmaceutical are also among the group's highest-rated stocks. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."